Literature DB >> 16271917

Aspirin use for the primary prevention of coronary heart disease in older adults.

Nicolas Rodondi1, Eric Vittinghoff, Jacques Cornuz, Javed Butler, Jingzhong Ding, Suzanne Satterfield, Anne B Newman, Tamara B Harris, Stephen B Hulley, Douglas C Bauer.   

Abstract

PURPOSE: Aspirin for the primary prevention of coronary heart disease (has a more favorable risk/benefit profile among adults with high coronary heart disease risk than among low-risk adults, but there is little information on the current patterns of aspirin use for primary prevention. We determined the prevalence of aspirin use in relation to coronary heart disease risk and changes over time. SUBJECTS AND METHODS: We measured regular aspirin use in 2163 black and white older adults without cardiovascular disease in a population-based cohort from 1997 to 1998 and 2002 to 2003. We determined the 10-year coronary heart disease risk by using the Framingham risk score.
RESULTS: In 1997-1998, 17% of the cohort were regular aspirin users. Aspirin use increased with coronary heart disease risk from 13% in persons with a 10-year risk less than 6% (low risk) to 23% in those with a 10-year risk greater than 20% (highest risk) (P for trend < .001). Blacks were less likely to use aspirin (13%) than whites (20%). In multivariate analysis, black race was still associated with lower aspirin use (odds ratio 0.66, 95% confidence interval 0.49-0.89). In 1997-1998 and 2002 to 2003, aspirin use increased from 17% to 32% among those still free of coronary heart disease (P < .001), and the association with coronary heart disease risk continued (P for trend < .001). Despite their high coronary heart disease risk, diabetic persons were not more likely to use aspirin than nondiabetic persons, even in 2002 and 2003 (odds ratio 0.89, 95% confidence interval 0.56-1.40).
CONCLUSION: Regular use of aspirin by older adults with no history of cardiovascular disease has increased in recent years. Individuals at higher coronary heart disease risk are more likely to take aspirin, but there is room for considerable improvement in targeting those at high risk, particularly diabetic persons and blacks.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16271917     DOI: 10.1016/j.amjmed.2005.06.020

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  9 in total

Review 1.  Coronary heart disease risk factors and outcomes in the twenty-first century: findings from the REasons for Geographic and Racial Differences in Stroke (REGARDS) Study.

Authors:  Hemal Bhatt; Monika Safford; Stephen Glasser
Journal:  Curr Hypertens Rep       Date:  2015-04       Impact factor: 5.369

2.  Aspirin Use for Cardiovascular Disease Prevention in an African American Population: Prevalence and Associations with Health Behavior Beliefs.

Authors:  Jeremy R Van't Hof; Sue Duval; Jeffrey R Misialek; Niki C Oldenburg; Clarence Jones; Milton Eder; Russell V Luepker
Journal:  J Community Health       Date:  2019-06

3.  Comparison of the racial/ethnic prevalence of regular aspirin use for the primary prevention of coronary heart disease from the multi-ethnic study of atherosclerosis.

Authors:  Daniel R Sanchez; Ana V Diez Roux; Erin D Michos; Roger S Blumenthal; Pamela J Schreiner; Gregory L Burke; Karol Watson
Journal:  Am J Cardiol       Date:  2011-01       Impact factor: 2.778

4.  Racial differences in antilipemic use and lipid control in high-risk older adults: post-Medicare Part D.

Authors:  Joseph T Hanlon; Robert M Boudreau; Subashan Perera; Elsa S Strotmeyer; Anne B Newman; Eleanor M Simonsick; Ronald I Shorr; Douglas C Bauer; Julie M Donohue
Journal:  Am Heart J       Date:  2013-08-28       Impact factor: 4.749

5.  Does differential prophylactic aspirin use contribute to racial and geographic disparities in stroke and coronary heart disease (CHD)?

Authors:  Stephen P Glasser; Mary Cushman; Ronald Prineas; Dawn Kleindorfer; Valerie Prince; Zhiying You; Virginia J Howard; George Howard
Journal:  Prev Med       Date:  2008-05-27       Impact factor: 4.018

6.  Underutilization of aspirin for primary prevention of cardiovascular disease among HIV-infected patients.

Authors:  Greer A Burkholder; Ashutosh R Tamhane; Jorge L Salinas; Michael J Mugavero; James L Raper; Andrew O Westfall; Michael S Saag; James H Willig
Journal:  Clin Infect Dis       Date:  2012-08-31       Impact factor: 9.079

7.  A 16-month community-based intervention to increase aspirin use for primary prevention of cardiovascular disease.

Authors:  Niki C Oldenburg; Sue Duval; Russell V Luepker; John R Finnegan; Heather LaMarre; Kevin A Peterson; Nicole D Zantek; Ginny Jacobs; Robert J Straka; Karen H Miller; Alan T Hirsch
Journal:  Prev Chronic Dis       Date:  2014-05-15       Impact factor: 2.830

8.  Use of non-steroidal anti-inflammatory drugs in US adults: changes over time and by demographic.

Authors:  Jennifer S Davis; Hwa Young Lee; Jihye Kim; Shailesh M Advani; Ho-Lan Peng; Emilyn Banfield; Ernest T Hawk; Shine Chang; Alexis C Frazier-Wood
Journal:  Open Heart       Date:  2017-04-28

9.  Low-Dose Aspirin for Primary Prevention of Cardiovascular Disease: Use Patterns and Impact Across Race and Ethnicity in the Southern Community Cohort Study.

Authors:  Rodrigo Fernandez-Jimenez; Thomas J Wang; Valentin Fuster; William J Blot
Journal:  J Am Heart Assoc       Date:  2019-12-11       Impact factor: 5.501

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.